• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Targeting cellular signalling pathways for disease therapy: the potential of cellular reprogramming and protein kinase inhibitors.

作者信息

Marensi Vanessa, Oliveira Pedro Fontes, Zamoner Ariane

机构信息

Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.

LAQV-REQUIMTE and Department of Chemistry, University of Aveiro, Aveiro, Portugal.

出版信息

Front Pharmacol. 2025 Mar 19;16:1580686. doi: 10.3389/fphar.2025.1580686. eCollection 2025.

DOI:10.3389/fphar.2025.1580686
PMID:40176899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11961961/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ff/11961961/d3d67bb34c14/fphar-16-1580686-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ff/11961961/d3d67bb34c14/fphar-16-1580686-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78ff/11961961/d3d67bb34c14/fphar-16-1580686-g001.jpg

相似文献

1
Editorial: Targeting cellular signalling pathways for disease therapy: the potential of cellular reprogramming and protein kinase inhibitors.社论：针对细胞信号通路进行疾病治疗：细胞重编程和蛋白激酶抑制剂的潜力
Front Pharmacol. 2025 Mar 19;16:1580686. doi: 10.3389/fphar.2025.1580686. eCollection 2025.
2
Recent advances in the role of AMP-activated protein kinase in metabolic reprogramming of metastatic cancer cells: targeting cellular bioenergetics and biosynthetic pathways for anti-tumor treatment.AMP激活蛋白激酶在转移性癌细胞代谢重编程中的作用的最新进展：针对细胞生物能量学和生物合成途径进行抗肿瘤治疗
J Physiol Pharmacol. 2018 Jun;69(3). doi: 10.26402/jpp.2018.3.07. Epub 2018 Sep 28.
3
Identification of Small-Molecule Inhibitors Targeting Different Signaling Pathways in Cancer-Associated Fibroblast Reprogramming under Tumor-Stroma Interaction.肿瘤-基质相互作用下癌症相关成纤维细胞重编程中靶向不同信号通路的小分子抑制剂的鉴定
J Invest Dermatol. 2025 Jan;145(1):65-76.e13. doi: 10.1016/j.jid.2024.04.026. Epub 2024 Jun 5.
4
Metabolic Reprogramming in Thyroid Cancer.甲状腺癌中的代谢重编程。
Endocrinol Metab (Seoul). 2024 Jun;39(3):425-444. doi: 10.3803/EnM.2023.1802. Epub 2024 Jun 10.
5
Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer.将RNA干扰与激酶抑制剂相结合，针对癌症相关的细胞信号传导成分。
BMC Cancer. 2005 Oct 3;5:125. doi: 10.1186/1471-2407-5-125.
6
Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase.鉴定致癌靶点 EGFR1、PI3K 和 BRAF 激酶的多激酶变构抑制剂。
Curr Comput Aided Drug Des. 2022;18(7):506-518. doi: 10.2174/1573409919666221031110341.
7
Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.通过蛋白激酶抑制剂将多形性胶质母细胞瘤细胞重编程为神经元。
J Exp Clin Cancer Res. 2018 Aug 2;37(1):181. doi: 10.1186/s13046-018-0857-5.
8
MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits.丝裂原活化蛋白激酶信号通路作为抗炎治疗的分子靶点——从分子机制到治疗益处
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):253-62. doi: 10.1016/j.bbapap.2005.08.017. Epub 2005 Sep 8.
9
Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics.内异症中的激酶信号通路：非激素治疗的潜在靶点。
Hum Reprod Update. 2016 Apr;22(3):382-403. doi: 10.1093/humupd/dmv060. Epub 2016 Jan 5.
10
Low-dose DNA demethylating therapy induces reprogramming of diverse cancer-related pathways at the single-cell level.低剂量 DNA 去甲基化治疗在单细胞水平诱导多种与癌症相关的通路重编程。
Clin Epigenetics. 2020 Sep 21;12(1):142. doi: 10.1186/s13148-020-00937-y.

本文引用的文献

1
The plasticity of epithelial cells and its potential in the induced differentiation of gastric cancer.上皮细胞的可塑性及其在胃癌诱导分化中的潜力。
Cell Death Discov. 2024 Dec 24;10(1):512. doi: 10.1038/s41420-024-02275-x.
2
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.靶向 RAS/RAF/MAPK 通路治疗癌症：从机制到临床研究。
Signal Transduct Target Ther. 2023 Dec 18;8(1):455. doi: 10.1038/s41392-023-01705-z.
3
Cellular plasticity in reprogramming, rejuvenation and tumorigenesis: a pioneer TF perspective.
重编程、细胞年轻化及肿瘤发生过程中的细胞可塑性：先驱转录因子视角
Trends Cell Biol. 2024 Mar;34(3):255-267. doi: 10.1016/j.tcb.2023.07.013. Epub 2023 Aug 28.
4
PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.PI3K/AKT 信号通路允许 MAPK/ERK 通路独立，介导黑色素瘤去分化驱动的治疗耐药性。
Cell Commun Signal. 2022 Nov 24;20(1):187. doi: 10.1186/s12964-022-00989-y.
5
IP-Se-06, a Selenylated Imidazo[1,2-]pyridine, Modulates Intracellular Redox State and Causes Akt/mTOR/HIF-1 and MAPK Signaling Inhibition, Promoting Antiproliferative Effect and Apoptosis in Glioblastoma Cells.IP-Se-06，一种硒代咪唑并[1,2-a]吡啶，调节细胞内氧化还原状态，并导致 Akt/mTOR/HIF-1 和 MAPK 信号通路抑制，从而促进神经胶质瘤细胞的抗增殖作用和细胞凋亡。
Oxid Med Cell Longev. 2022 Mar 22;2022:3710449. doi: 10.1155/2022/3710449. eCollection 2022.
6
Reconstruction and analysis of a large-scale binary Ras-effector signaling network.重建和分析大规模的二元 Ras 效应子信号网络。
Cell Commun Signal. 2022 Mar 4;20(1):24. doi: 10.1186/s12964-022-00823-5.
7
Targeting PI3K/Akt signal transduction for cancer therapy.针对 PI3K/Akt 信号转导通路的癌症治疗策略。
Signal Transduct Target Ther. 2021 Dec 16;6(1):425. doi: 10.1038/s41392-021-00828-5.
8
The tumor microenvironment.肿瘤微环境。
Curr Biol. 2020 Aug 17;30(16):R921-R925. doi: 10.1016/j.cub.2020.06.081.
9
Hallmarks of cancer: the next generation.癌症的特征：下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
10
Protein kinases--the major drug targets of the twenty-first century?蛋白激酶——21世纪的主要药物靶点？
Nat Rev Drug Discov. 2002 Apr;1(4):309-15. doi: 10.1038/nrd773.